{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:01:22Z","timestamp":1786377682617,"version":"build-2736575974"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AstraZeneca"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Ceftaroline could be suitable to treat early-onset ventilator-associated pneumonia (VAP) because of its antibacterial spectrum. However, augmented renal clearance (ARC) is frequent in ICU patients and may affect ceftaroline pharmacokinetics and efficacy. The objective of the study was to explore the impact of ARC on ceftaroline pharmacokinetics and evaluate whether the currently recommended dosing regimen (600\u2005mg every 12\u2005h) is appropriate to treat VAP in ICU patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A population pharmacokinetic model was developed using pharmacokinetic data from 18 patients with measured creatinine clearance (CLCR) ranging between 83 and 309\u2005mL\/min. Monte Carlo simulations were conducted to determine the PTA and the cumulative fraction of response (CFR) against Streptococcus pneumoniae and MRSA for five dosing regimens. Study registered at ClinicalTrials.gov (NCT03025841).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ceftaroline clearance increased non-linearly with CLCR, with lower concentrations and lower probability of reaching pharmacokinetic\/pharmacodynamic targets when CLCR increases. For the currently recommended dosing regimen, the probability of having unbound ceftaroline concentrations above the MIC over the entire dose range is greater than 90% for MICs below 0.125\u2005mg\/L. Considering the distribution of MICs, this regimen would not be effective against MRSA infections (CFR between 21% and 67% depending on CLCR), but would be effective against S. pneumoniae infections (CFR &amp;gt;86%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The recommended dosing regimen of ceftaroline seems sufficient for covering S. pneumoniae in ICU patients with ARC, but not for MRSA. Among the dosing regimens tested it appears that a constant infusion (50\u2005mg\/h) after a loading dose of 600\u2005mg could be more appropriate for MRSA infections.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkac299","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T05:19:00Z","timestamp":1662355140000},"page":"3173-3179","source":"Crossref","is-referenced-by-count":17,"title":["Population pharmacokinetic\/pharmacodynamic study suggests continuous infusion of ceftaroline daily dose in ventilated critical care patients with early-onset pneumonia and augmented renal clearance"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-5888","authenticated-orcid":false,"given":"Alexia","family":"Chauzy","sequence":"first","affiliation":[{"name":"INSERM U1070, Pharmacologie des Anti-infectieux et Antibior\u00e9sistance , Poitiers , France"},{"name":"Universit\u00e9 de Poitiers, UFR de M\u00e9decine Pharmacie , Poitiers , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gregoire","sequence":"additional","affiliation":[{"name":"INSERM U1070, Pharmacologie des Anti-infectieux et Antibior\u00e9sistance , Poitiers , France"},{"name":"Universit\u00e9 de Poitiers, UFR de M\u00e9decine Pharmacie , Poitiers , France"},{"name":"CHU de Poitiers, Laboratoire de Toxicologie-Pharmacocin\u00e9tique , Poitiers , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Ferrandi\u00e8re","sequence":"additional","affiliation":[{"name":"Groupe ATLANREA, CHU de Nantes , Nantes , France"},{"name":"CHU de Tours, Service d\u2019Anesth\u00e9sie-R\u00e9animation , Tours , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigismond","family":"Lasocki","sequence":"additional","affiliation":[{"name":"Groupe ATLANREA, CHU de Nantes , Nantes , France"},{"name":"CHU d\u2019Angers, Service d\u2019Anesth\u00e9sie-R\u00e9animation , Angers , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Ashenoune","sequence":"additional","affiliation":[{"name":"Groupe ATLANREA, CHU de Nantes , Nantes , France"},{"name":"CHU de Nantes, Service d\u2019Anesth\u00e9sie-R\u00e9animation, H\u00f4tel Dieu - HME , Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-4257","authenticated-orcid":false,"given":"Philippe","family":"Seguin","sequence":"additional","affiliation":[{"name":"Groupe ATLANREA, CHU de Nantes , Nantes , France"},{"name":"CHU de Rennes, Service d\u2019Anesth\u00e9sie-R\u00e9animation, Pontchaillou , Rennes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3667-5782","authenticated-orcid":false,"given":"Matthieu","family":"Boisson","sequence":"additional","affiliation":[{"name":"INSERM U1070, Pharmacologie des Anti-infectieux et Antibior\u00e9sistance , Poitiers , France"},{"name":"Universit\u00e9 de Poitiers, UFR de M\u00e9decine Pharmacie , Poitiers , France"},{"name":"Groupe ATLANREA, CHU de Nantes , Nantes , France"},{"name":"CHU de Poitiers, Service d\u2019Anesth\u00e9sie-R\u00e9animation et M\u00e9decine P\u00e9riop\u00e9ratoire , Poitiers , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Couet","sequence":"additional","affiliation":[{"name":"INSERM U1070, Pharmacologie des Anti-infectieux et Antibior\u00e9sistance , Poitiers , France"},{"name":"Universit\u00e9 de Poitiers, UFR de M\u00e9decine Pharmacie , Poitiers , France"},{"name":"CHU de Poitiers, Laboratoire de Toxicologie-Pharmacocin\u00e9tique , Poitiers , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marchand","sequence":"additional","affiliation":[{"name":"INSERM U1070, Pharmacologie des Anti-infectieux et Antibior\u00e9sistance , Poitiers , France"},{"name":"Universit\u00e9 de Poitiers, UFR de M\u00e9decine Pharmacie , Poitiers , France"},{"name":"CHU de Poitiers, Laboratoire de Toxicologie-Pharmacocin\u00e9tique , Poitiers , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-7915","authenticated-orcid":false,"given":"Olivier","family":"Mimoz","sequence":"additional","affiliation":[{"name":"INSERM U1070, Pharmacologie des Anti-infectieux et Antibior\u00e9sistance , Poitiers , France"},{"name":"Universit\u00e9 de Poitiers, UFR de M\u00e9decine Pharmacie , Poitiers , France"},{"name":"Groupe ATLANREA, CHU de Nantes , Nantes , France"},{"name":"CHU de Poitiers, Service des Urgences & SAMU 86 , Poitiers , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dahyot-Fizelier","sequence":"additional","affiliation":[{"name":"INSERM U1070, Pharmacologie des Anti-infectieux et Antibior\u00e9sistance , Poitiers , France"},{"name":"Universit\u00e9 de Poitiers, UFR de M\u00e9decine Pharmacie , Poitiers , France"},{"name":"Groupe ATLANREA, CHU de Nantes , Nantes , France"},{"name":"CHU de Poitiers, Service d\u2019Anesth\u00e9sie-R\u00e9animation et M\u00e9decine P\u00e9riop\u00e9ratoire , Poitiers , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"issue":"Suppl 4","key":"2022102819181145200_dkac299-B1","first-page":"iv41","article-title":"CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"2022102819181145200_dkac299-B2","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2022102819181145200_dkac299-B3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijid.2018.10.004","article-title":"Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America","volume":"77","author":"Sader","year":"2018","journal-title":"Int J Infect Dis"},{"key":"2022102819181145200_dkac299-B4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.01324-08","article-title":"In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae","volume":"53","author":"McGee","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2022102819181145200_dkac299-B5","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00097-16","article-title":"Single- and repeated-dose pharmacokinetics of ceftaroline in plasma and soft tissues of healthy volunteers for two different dosing regimens of ceftaroline fosamil","volume":"60","author":"Matzneller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022102819181145200_dkac299-B6","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1128\/AAC.00498-15","article-title":"Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects","volume":"59","author":"Justo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022102819181145200_dkac299-B7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/jcph.265","article-title":"A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis","volume":"54","author":"Riccobene","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2022102819181145200_dkac299-B8","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jcf.2017.10.010","article-title":"Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis","volume":"17","author":"Barsky","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2022102819181145200_dkac299-B9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/jcph.153","article-title":"Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"53","author":"Van Wart","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"2022102819181145200_dkac299-B10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jac\/dky489","article-title":"Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain","volume":"74","author":"Chauzy","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022102819181145200_dkac299-B11","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1345\/aph.1Q225","article-title":"Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"45","author":"Jorgenson","year":"2011","journal-title":"Ann Pharmacother"},{"key":"2022102819181145200_dkac299-B12","author":"EMA","year":"2018"},{"key":"2022102819181145200_dkac299-B13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/cc13775","article-title":"Ventilator-associated pneumonia in the ICU","volume":"18","author":"Kalanuria","year":"2014","journal-title":"Crit Care"},{"key":"2022102819181145200_dkac299-B14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient\u2014concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"2022102819181145200_dkac299-B15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.11-1671","article-title":"Subtherapeutic initial \u03b2-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations","volume":"142","author":"Udy","year":"2012","journal-title":"Chest"},{"key":"2022102819181145200_dkac299-B16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijid.2020.02.044","article-title":"Impact of augmented renal clearance on the pharmacokinetics of linezolid: advantages of continuous infusion from a pharmacokinetic\/pharmacodynamic perspective","volume":"93","author":"Barrasa","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2022102819181145200_dkac299-B17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/CCM.0000000000000029","article-title":"Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations","volume":"42","author":"Udy","year":"2014","journal-title":"Crit Care Med"},{"key":"2022102819181145200_dkac299-B18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/ACO.0000000000000830","article-title":"Multidrug-resistant bacteria in ICU: fact or myth","volume":"33","author":"De Waele","year":"2020","journal-title":"Curr Opin Anaesthesiol"},{"key":"2022102819181145200_dkac299-B19","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022102819181145200_dkac299-B20","author":"EUCAST"},{"key":"2022102819181145200_dkac299-B21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2022102819181145200_dkac299-B22","author":"EUCAST","year":"2020"},{"key":"2022102819181145200_dkac299-B23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dky439","article-title":"Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections","volume":"74","author":"Das","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022102819181145200_dkac299-B24","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function \u2014 measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med"},{"key":"2022102819181145200_dkac299-B25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ckj\/sfw071","article-title":"Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?","volume":"9","author":"Delanaye","year":"2016","journal-title":"Clin Kidney J"},{"key":"2022102819181145200_dkac299-B26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1186\/s13054-014-0657-z","article-title":"Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds","volume":"18","author":"Udy","year":"2014","journal-title":"Crit Care"},{"key":"2022102819181145200_dkac299-B27","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.50.4.1376-1383.2006","article-title":"Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022102819181145200_dkac299-B28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s13054-020-03272-z","article-title":"Failure of target attainment of \u03b2-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)","volume":"24","author":"Abdulla","year":"2020","journal-title":"Crit Care"},{"key":"2022102819181145200_dkac299-B29","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1136\/ejhpharm-2017-001221","article-title":"Physical and chemical stability of ceftaroline in an elastomeric infusion device","volume":"25","author":"Al Madfai","year":"2018","journal-title":"Eur J Hosp Pharm Sci Pract"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/11\/3173\/46680353\/dkac299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/11\/3173\/46680353\/dkac299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T13:25:19Z","timestamp":1701005119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/11\/3173\/6691803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,9,5]]},"published-print":{"date-parts":[[2022,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac299","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,2]]},"published":{"date-parts":[[2022,9,5]]}}}